Sophia Genetics has raised $30 million in Series D funding in a bid to accelerate its mission of democratising data-driven medicine worldwide.

The company’s universal technology, Sophia AI accurately analyses and detects all types of genomic variants to help clinicians better diagnose and treat their patients.

The new round of funding will not only enable the company to continue with its mission, but also use the necessary resources to further develop its technology. The company will continue to recruit top talent and accelerate hospitals’ adoption of clinical genomics testing, regardless of whether they are equipped with a next-generation DNA sequencing lab or not.

CEO and Co-Founder, Dr Jurgi Camblong told Front Line Genomics: “Our AI technology is today being deployed in 350 hospitals that are all connected to each other by a software service programme, to diagnose about  8,000 patients per month and have analysed over 125,000 patients in 53 countries to date.”

“Back in 2014, when we first launched the platform we decided to focus first on Europe and now that we have demonstrated that the technology works effectively independently we will be raising deployment in hospitals outside of Europe. Part of the money will be used for that extended network of users. We will continuously improve our technology to better support the patient workflow in patient oncology, not only in molecular imaging data but as well as being able to use the platform so that pathologists will be able to communicate with oncologists regarding the treatment patients receive.”

With more and more hospitals adopting Sophia AI the company has in turn created the largest clinical genomics community, which enables the hundreds of institutions in the network to safely and anonymously share their findings and knowledge while ensuring patient data privacy.

“I think that the beauty is that all hospitals today are capable of doing precision medicine by just using AI,” explains Dr Jurgi. “That is really the magic; through the use of technology we use a barrier for hospitals who want to jump into genomic medicine by enabling every hospital in the world who can afford it to be as good as every university hospital.”